Yue Zhang

Yue Zhang

Auto-generated profile, based on publicly available information

Yue Zhang

Multitude Therapeutics, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
WWWeining Weng
Weining Weng
TMTao Meng
Tao Meng
QZQianqian Zhao
Qianqian Zhao
YSYi Shen
Yi Shen
GFGuoxiang Fu
Guoxiang Fu
XMXun Meng
Xun Meng
Antibody–drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have transformed cancer treatment, yet more effective ADCs are needed for overcoming resistance. We have designed an ADC class using a novel self-immolative T moiety for traceless conjugation and release of exatecan, a more potent topoisomerase I inhibitor with less sensitivity to multidrug resistance (MDR). Characterized by enhanced therapeutic indices, higher stability, and improved intratumoral pharmacodynamic response, antibody–T moiety–exatecan conjugates targeting HER2, HER3, and TROP2 overcome the intrinsic or treatment resistance of equivalent DXd/SN-38 ADCs in low-target-expression, large, and MDR+ tumors. T moiety–exatecan ADCs display durable antitumor activity in patient-derived xenograft and organoid models representative of unmet clinical needs, including EGFR ex19del/T790M/C797S triple-mutation lung cancer and BRAF/KRAS–TP53 double-mutant colon cancer, and show synergy with PARP/ATR inhibitor and anti–PD-1 treatment. High tolerability of the T moiety–exatecan ADC class in nonhuman primates supports its potential to expand the responding patient population and tumor types beyond current ADCs. Significance: ADCs combining a novel self-immolative moiety and topoisomerase I inhibitor exatecan as payload show deep and durable response in low-target-expressing and MDR+ tumors resistant to DXd/SN-38 ADCs without increasing toxicity. This new class of ADCs has the potential to benefit an additional patient population beyond current options. See related commentary by Gupta et al., p. 817. This article is highlighted in the In This Issue feature, p. 799

25 May 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
TPThomas T. Poulsen
Thomas T. Poulsen
OIOlga Ilina
Olga Ilina
JWJonathan H. Wardman
Jonathan H. Wardman
ABAnne Bie
Anne Bie
JBJette Bornholdt
Jette Bornholdt
DMDominik Mumberg
Dominik Mumberg
Tissue factor (TF) protein is involved in activating the extrinsic blood coagulation cascade. TF expression is normally anatomically limited to the perivascular space, but TF is overexpressed in many malignancies, including pancreatic, cervical, prostate, and head and neck cancers, which makes TF an ideal antibody–drug conjugate (ADC) target. The TF-ADC tisotumab vedotin is approved for cervical cancer treatment but induces substantial side effects including ocular toxicities, peripheral neuropathy, and bleeding, limiting its further clinical development and warranting optimized ADC design to improve the therapeutic window. ADCE-T02 is a novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the topoisomerase 1 inhibitor exatecan at an average drug-to-antibody ratio of 4.5. In contrast to tisotumab, Ab-T02 does not inhibit coagulation factor X activation. ADCE-T02 binds TF with high affinity inducing ADC internalization, exatecan release, cancer cell death, and bystander cytotoxicity in vitro. In vivo, ADCE-T02 is highly efficacious across a range of cell line–derived and patient-derived xenograft models including hard-to-treat models with large tumors, resistance to standard of care, low and/or heterogeneous expression of TF, and multidrug resistance. Importantly, ADCE-T02 demonstrates favorable pharmacokinetic properties and is well tolerated in nonhuman primates and in contrast to tisotumab vedotin and other auristatin-based ADCs shows no evidence of ocular, skin, and lung toxicities; peripheral nerve damage; or bleeding. In summary, ADCE-T02 constitutes a novel TF-ADC with a much improved preclinical therapeutic window. Phase I clinical development of ADCE-T02 in patients with advanced solid tumors is ongoing (ClinicalTrials ID: NCT06597721).

27 February 2023 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
JYJane Yardley
Jane Yardley
XZXiaoyan Zhu
Xiaoyan Zhu
YZYue Zhang
Yue Zhang
FLFei Liang
Fei Liang
JYJieyun Yin
Jieyun Yin
NBNormand Boul
Normand Boul

3 April 2023
Verified
Other
Open access
WWWeining Weng
Weining Weng
TMTao Meng
Tao Meng
QZQianqian Zhao
Qianqian Zhao
YSYi Shen
Yi Shen
GFGuoxiang Fu
Guoxiang Fu
XMXun Meng
Xun Meng
Supplementary Table S1 shows cytotoxicity of exatecan compared to DXd. Supplementary Table S2 shows selected hematologic parameters and biochemical parameters from the repeat-dose administration of exatecan mesylate studies in rats. Supplementary Table S3 shows in vitro ADC stability study of total antibody, ADC and free payload. Supplementary Table S4 shows pharmacokinetic parameters of total antibody, ADC and free payload. Supplementary Table S5 shows ADC (T: T-1000-e; D: DS-8201a) internalization rate on cell lines with different HER2 expression level. Supplementary Table S6 shows correlation of exatecan release and target expression. Supplementary Table S7 shows In vitro cytotoxicicity of HER-targeting MTX-1000, TROP2 targeting MTX-132 and HER3-targeting Patritumab-T1000-exatecan and their counterpart DXd-ADC.

4 April 2023
Verified
Other
Open access
WWWeining Weng
Weining Weng
TMTao Meng
Tao Meng
QZQianqian Zhao
Qianqian Zhao
YSYi Shen
Yi Shen
GFGuoxiang Fu
Guoxiang Fu
XMXun Meng
Xun Meng
Supplementary Figure S1 shows Exatecan cytotoxicity and sensitivity to multidrug resistant genes. Supplementary Figure S2 shows Exatecan and DXd/SN-38 sensitivity to multidrug resistant genes. Supplementary Figure S3 shows Exatecan toxicity in rat. Supplementary Figure S4 shows the design and optimization of T moiety. Supplementary Figure S5 shows physicochemical and functional equivalence of Tras-GGFG-DXd and DS-8201a. Supplementary Figure S6 show physicochemical profile of antibody-exatecan conjugates enabled by T moiety. Supplementary Figure S7 shows additional T moiety-exatecan and belotecan conjugates. Supplementary Figure S8 shows in vitro and in vivo stability of MTX-1000. Supplementary Figure S9 shows cellular dynamics and mechanism of MTX-1000. Supplementary Figure S10 shows colon cancer organoid response to ADCs. Supplementary Figure S11 shows bystander killing effect of MTX-1000, T-DM1 and Tras-GGFG-DXd in coculture conditions in vitro. Supplementary Figure S12 shows hematology and serum chemistry of MTX-1000 in monkey. Supplementary Figure S13 shows T moiety-exatecan ADCs show potent antitumor efficacy and improved therapeutic index. Supplementary Figure S14 shows T moiety-exatecan ADCs show higher antitumor potency in PDX models and better intratumor pharmacodynamic response. Supplementary Figure S15 shows T moiety-exatecan ADCs overcome treatment-resistance due to improved therapeutic index and intratumor pharmacodynamic response. Supplementary Figure S16 shows overcoming MDR resistance by T moiety exatecan ADCs or a combination of MDR inhibitor with DXd/SN-38 ADCs. Supplementary Figure S17 shows Exatecan/MTX-1000 and PARP/ATR inhibitor synergize in colon cancer cells. Supplementary Figure S18 shows a patient-derived xenograft (PDX) model with EGFR triple mutation. Supplementary Figure S19 shows MTX-1000 induces immunological cell death and enhances antitumor immunity of anti-PD-1.

4 April 2023
Verified
Other
Open access
WWWeining Weng
Weining Weng
TMTao Meng
Tao Meng
QZQianqian Zhao
Qianqian Zhao
YSYi Shen
Yi Shen
GFGuoxiang Fu
Guoxiang Fu
XMXun Meng
Xun Meng
Supplementary note shows the analytical characterization of the ADCs, and synthesis of drug-linkers